

Roberta Palla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1838653/publications.pdf>

Version: 2024-02-01

62
papers

2,697
citations

201385

27
h-index

182168

51
g-index

64
all docs

64
docs citations

64
times ranked

2230
citing authors

#	ARTICLE	IF	CITATIONS
1	Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 615-621.	1.9	362
2	ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. <i>Haematologica</i> , 2008, 93, 232-239.	1.7	250
3	Rare bleeding disorders: diagnosis and treatment. <i>Blood</i> , 2015, 125, 2052-2061.	0.6	244
4	ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. <i>Human Mutation</i> , 2010, 31, 11-19.	1.1	165
5	Genetic diagnosis of haemophilia and other inherited bleeding disorders. <i>Haemophilia</i> , 2006, 12, 82-89.	1.0	123
6	Introduction: Rare Bleeding Disorders: General Aspects of Clinical Features, Diagnosis, and Management. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 349-355.	1.5	123
7	ADAMTS-13 assays in thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 631-640.	1.9	103
8	Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1887-1890.	1.9	98
9	Rare bleeding disorders. <i>Haemophilia</i> , 2006, 12, 137-142.	1.0	76
10	ADAMTS13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1556-1565.	1.9	74
11	Risk factors for inhibitor development in severe hemophilia A. <i>Thrombosis Research</i> , 2018, 168, 20-27.	0.8	67
12	Rare Bleeding Disorders: Worldwide Efforts for Classification, Diagnosis, and Management. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 579-584.	1.5	58
13	Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1534-1541.	1.9	57
14	Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. <i>Free Radical Biology and Medicine</i> , 2010, 48, 446-456.	1.3	56
15	The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. <i>Blood</i> , 2006, 108, 1280-1283.	0.6	52
16	Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2010, 151, 488-494.	1.2	46
17	Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. <i>Blood</i> , 2017, 130, 1757-1759.	0.6	44
18	Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13. <i>Journal of Biological Chemistry</i> , 2005, 280, 23295-23302.	1.6	43

#	ARTICLE	IF	CITATIONS
19	Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. <i>Blood</i> , 2017, 129, 1245-1250.	0.6	41
20	Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 695-704.	1.8	41
21	Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. <i>Human Mutation</i> , 2006, 27, 330-336.	1.1	39
22	Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 39-43.	1.9	39
23	The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 2322-2325.	0.7	37
24	Minimal factor XIII activity level to prevent major spontaneous bleeds. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1728-1736.	1.9	34
25	Hemostatic alterations in COVID-19. <i>Haematologica</i> , 2021, 106, 1472-1475.	1.7	34
26	Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2053-2062.	1.9	31
27	The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na ⁺ binding. <i>FEBS Journal</i> , 2006, 273, 159-169.	2.2	30
28	Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. <i>Thrombosis and Haemostasis</i> , 2011, 105, 381-385.	1.8	27
29	SIPPET: methodology, analysis and generalizability. <i>Haemophilia</i> , 2017, 23, 353-361.	1.0	27
30	Mechanistic Studies on ADAMTS13 Catalysis. <i>Biophysical Journal</i> , 2008, 95, 2450-2461.	0.2	22
31	The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura. <i>Haematologica</i> , 2009, 94, 289-293.	1.7	22
32	Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. <i>Thrombosis Research</i> , 2016, 148, 128-134.	0.8	22
33	Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura. <i>Haematologica</i> , 2010, 95, 1444-1447.	1.7	19
34	Active platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1653-1656.	1.9	19
35	FRET-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. <i>Thrombosis and Haemostasis</i> , 2014, 112, 297-303.	1.8	19
36	Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF). <i>Journal of Biological Chemistry</i> , 2006, 281, 30400-30411.	1.6	17

#	ARTICLE	IF	CITATIONS
37	Role of the 2 adenine (g.11293_11294insAA) insertion polymorphism in the 3' untranslated region of the factor VII (FVII) gene: molecular characterization of a patient with severe FVII deficiency. Human Mutation, 2005, 26, 455-461.	1.1	16
38	Measurement of anti-ADAMTS13 neutralizing autoantibodies: a comparison between CBA and FRET assays. Journal of Thrombosis and Haemostasis, 2012, 10, 1439-1442.	1.9	16
39	Pitfalls in molecular diagnosis in a family with severe factor VII (FVII) deficiency? misdiagnosis by direct sequence analysis using a PCR product. Prenatal Diagnosis, 2003, 23, 731-734.	1.1	15
40	Potential misdiagnosis of dysfibrinogenemia: Data from multicentre studies amongst UK NEQAS and PRO-BDD project laboratories. International Journal of Laboratory Hematology, 2017, 39, 653-662.	0.7	13
41	An international registry of patients with plasminogen deficiency (HISTORY). Haematologica, 2020, 105, 554-561.	1.7	13
42	High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. Blood Transfusion, 2018, 16, 215-220.	0.3	12
43	Clinical and laboratory diagnosis of rare coagulation disorders (RCDs). Thrombosis Research, 2020, 196, 603-608.	0.8	9
44	A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking. Thrombosis Research, 2014, 133, 481-487.	0.8	8
45	Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-BDD project laboratories. International Journal of Laboratory Hematology, 2017, 39, 350-358.	0.7	6
46	The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency. British Journal of Haematology, 2004, 127, 576-584.	1.2	5
47	B and T lymphocytes in acquired Thrombotic Thrombocytopenic Purpura during disease remission. Thrombosis Research, 2011, 128, 590-592.	0.8	5
48	Fibrinogen concentrates. Clinical Advances in Hematology and Oncology, 2009, 7, 788-90.	0.3	5
49	Congenital thrombotic thrombocytopenic purpura with novel mutations in three unrelated Turkish children. Pediatric Blood and Cancer, 2014, 61, 558-561.	0.8	4
50	Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A. Haematologica, 2019, 104, e369-e372.	1.7	4
51	DETERMINATION OF ANTI-ADAMTS13 AUTOANTIBODIES IN THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) PATIENTS: COMPARISON OF TWO DIFFERENT METHODS. Journal of Thrombosis and Haemostasis, 2007, 5, P-T-303-P-T-303.	1.9	2
52	IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. British Journal of Haematology, 2021, 192, 621-625.	1.2	1
53	Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia, 2021, 27, e441-e449.	1.0	1
54	Genetic Risk Stratification to Minimize Inhibitor Risk with the Use of Recombinant Factor VIII Concentrates: A Sippet Analysis. Blood, 2016, 128, 325-325.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Choices of factor <scp>VIII</scp> products in previously untreated patients with haemophilia A: A global survey. Haemophilia, 2018, 24, e266-e268.	1.0	0
56	Localization and Function of Platelet ADAMTS-13.. Blood, 2005, 106, 3967-3967.	0.6	0
57	Thrombospondin-1 as a Modulator of ADAMTS13 Activity.. Blood, 2007, 110, 3711-3711.	0.6	0
58	Diagnostic relevance of ADAMTS13 activity: Evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis. Srpski Arhiv Za Celokupno Lekarstvo, 2013, 141, 466-474.	0.1	0
59	Risk Differential in Inhibitor Development in the First Days of Treatment By Product Class: A Sippet Analysis. Blood, 2016, 128, 330-330.	0.6	0
60	Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study). Blood, 2016, 128, 207-207.	0.6	0
61	Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis". Blood Transfusion, 2019, 17, 86.	0.3	0
62	Factor VIII Epitope Analysis Using a Random Peptide Phage-Display Library Approach in the Sippet Cohort. Blood, 2021, 138, 3176-3176.	0.6	0